MAGE-A3 expression is an adverse prognostic factor in diffuse large B-cell lymphoma

Hematology

Volumn 16, Issue 6, 2011, Pages 368-372

  Olarte, Irma ^a   Martinez, Adolfo ^a   Ramos Peñafiel, Christian ^a   Castellanos Sinco, Humberto ^a   Zamora, Jorge ^a   Collazo Jaloma, Juan ^a   Gutiérrez, Mario ^a   Gutiérrez Kobeh, Laila ^b   Chavez Olmos, Pedro ^c   Manzanilla, Hugo ^a   Garrido Guerrer, Efraín ^c   Ordoñez Raz, Rosa M ^d   Miranda, Enrique I ^a,e  

^a HOSPITAL GENERAL DE MÉXICO   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c DEPARTAMENTO DE FÍSICA   (Mexico)

^d HOSPITAL DE PEDIATRÍA   (Mexico)

^e Universidad Westhill   (Mexico)

Author keywords

DLBCL; Expression; Lymphoma; MAGE A3; Prognostic

Indexed keywords

LACTATE DEHYDROGENASE; MELANOMA ANTIGEN 3;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; L-LACTATE DEHYDROGENASE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 82955164001     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453311X13085644680384     Document Type: Article

References (31)

1. Ng AK. Diffuse large B-cell lymphoma. Semin Radiat Oncol 2007;17:169-75.
2. Weigert O, Unterhalt M, Hiddemann W, Dreyling M. Current management of mantle cell lymphoma. Drugs 2007;67:1689-1702.
3. Richardson PG, Mitsiades C, Schlossman R, Munshi N, Anderson K. New drugs for myeloma. Oncologist 2007;12:664-89.
4. Coiffier B. Diffuse large cell lymphoma. Curr Opin Oncol 2001;13:325-34.
5. Lossos IS, Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 2006;24:995-1007.
6. Han MH, Eom HS, Park WS, Yun T, Park S, Kim HJ, et al. Detection of circulating lymphoma cells in patients with non- Hodgkin lymphoma using MAGE-A3 gene expression in peripheral blood. Leuk Res 2010;34:1127-31.
7. Miranda EI. MAGE, biological functions and potential clinical applications. Leuk Res 2010;34:1121-2.
8. Sienel W, Mecklenburg I, Dango S, Ehrhardt P, Kirschbaum A, Passlick B, et al. Detection of MAGE-A transcripts in bone marrow is an independent prognostic factor in operable nonsmall- cell lung cancer. Clin Cancer Res 2007;13:3840-7.
9. Condomines M, Hose D, Raynaud P, Hundemer M, de Vos J, Baudard M, et al. Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis. J Immunol 2007;178:3307-15.
10. Napoletano C, Bellati F, Tarquini E, Tomao F, Taurino F, Spagnoli G, et al. MAGE-A and NY-ESO-1 expression in cervical cancer: prognostic factors and effects of chemotherapy. Am J Obstet Gynecol 2008;198:99.e1-7.
11. Kocher T, Zheng M, Bolli M, Simon R, Forster T, Schultz- Thater E, et al. Prognostic relevance of MAGE-A4 tumor antigen expression in transitional cell carcinoma of the urinary bladder: a tissue microarray study. Int J Cancer 2002;100:702-5.
12. Martinez A, Olarte I, Mergold MA, Gutierrez M, Rozen E, Collazo J, et al. mRNA expression of MAGE-A3 gene in leukemia cells. Leuk Res 2007;31:33-7.
13. Miranda EI, Garrido-Guerrero E, García-Carrancá A, Gariglio P. Immunoprecipitation of SV40 replicating minichromosomes complexed with bacteriophage T4 gene 32 protein. Nucl Acids Res 1992;20:903-7.
14. Salazar AM, Ostrosky-Wegman P, Menéndez D, Miranda EI, García-Carrancá A, Rojas E. Induction of P53 protein expression by sodium arsenite. Mutat Res 1997;381:259-65.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
16. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
17. Czuczman MS, Grillo-López AJ, Alkuzweny B, Weaver R, Larocca A, McLaughlin P. Prognostic factors for non- Hodgkin's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab. Leuk Lymphoma 2006;47:1830-40.
18. Fisher RI, Miller TP, O'Connor OA. Diffuse aggressive lymphoma. Hematology Am Soc Hematol Educ Program 2004;:221-36.
19. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non- Hodgkin's lymphoma. N Engl J Med 1993;329:987-94.
20. Brasseur F, Rimoldi D, Liénard D, Lethé B, Carrel S, Arienti F, et al. Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 1995;63:375-80.
21. Kurashige T, Noguchi Y, Saika T, Ono T, Nagata Y, Jungbluth A, et al. NY-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade. Cancer Res 2001;61:4671-4.
22. Dhodapkar MV, Osman K, Teruya-Feldastein J, Filippa D, Hedvat CV, Iversen K, et al. Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7 and NYESO- 1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer Immun 2003;3:9-16.
23. Liggins AP, Lim SH, Soilleux EJ, Pulford K, Banham AH. A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies. Cancer Immun 2010;10:8-19.
24. Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, et al. Prediction of survival in diffuse large B-cell lymphoma based on the expression of six genes. N Engl J Med 2004;350:1828-37.
25. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-82.
26. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med 2002;346:1937-47.
27. Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68-74.
28. Kawano R, Karube K, Kikuchi M, Takeshita M, Tamura K, Uike N, et al. Oncogene associated cDNA microarray analyses shows PRAME gene expression is a marker for response to anthracycline containing chemotherapy in patients with diffuse large B-cell lymphoma. J Clin Exp Hematopathol 2009;49:1-7.
29. Maxwell SA, Li Z, Jaya D, Ballard S, Ferrell J, Fu H. 14-3-3f mediates resistance of diffuse large B-cell lymphoma to an anthracycline-based chemotherapeutic regimen. J Biol Chem 2009;284:22379-89.
30. Xie X, Wacker H, Huang S, Regitz E, Preuss K-D, Romeike B, et al. Differential expression of cancer testis genes in histological subtypes of non-Hodgkin's lymphomas. Clin Cancer Res 2003;9:167-73.
31. Ait-Tahar K, Liggins AP, Collins GP, Campbell A, Barnardo M, Lawrie C, et al. Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma. Br J Haematol 2009;146:396-407.